Kleinstein R N, Mutti D O, Manny R E, Shin J A, Zadnik K
University of Alabama at Birmingham School of Optometry, USA.
Optom Vis Sci. 1999 Feb;76(2):102-7. doi: 10.1097/00006324-199902000-00017.
The selection of a cycloplegic agent depends on the desired outcome, the characteristics of the patient receiving the drug, and the associated risks. The Orinda Longitudinal Study of Myopia (OLSM) has used 1% tropicamide to assess the ocular components and cycloplegic refractions in a large cohort of predominantly Caucasian children. Although tropicamide has provided adequate cycloplegia and mydriasis for the OLSM cohort, conventional clinical wisdom and scientific investigations have suggested that tropicamide might not produce adequate cycloplegia and mydriasis for subjects with darker iris pigmentation. In this study one drop of 1% tropicamide followed by one drop of 1% cyclopentolate was used to determine their effectiveness in producing adequate cycloplegia and mydriasis for cycloplegic refraction and ocular component measurements in a group of African-American children.
Nineteen children [age range 5.5 to 15.6 years, mean 8.4 years +/- (SD) 2.5 years] were tested at Family HealthCare of Alabama, Eutaw, AL. Their accommodative responses were measured using a Canon R-1 autorefractor prior to and at 30, 45, and 60 min after instillation of one drop of 0.5% proparacaine, 1% tropicamide (Mydriacyl), and 1% cyclopentolate (Cyclogyl) in both eyes. A target of 20/155 letters in a 4x4 grid positioned behind a +6.50 diopter (D) Badal lens provided accommodative stimuli of 1.00 D, 2.00 D, and 4.00 D.
All results are presented as mean +/-1 SD. Pupils, measured from video frames, dilated rapidly and maximally at 30 min after instillation of eye drops (7.3+/-0.5 mm) Predilation, the mean accommodative responses were 0.17+/-0.29 D for the 1.00 D stimulus, 1.01+/-0.40 D for the 2.00 D stimulus, and 2.77+/-0.74 for the 4.00 D stimulus. At 30 min after drop instillation, the responses were 0.07+/-0.14 D for the 1.00 D stimulus, 0.36+/-0.35 D for the 2.00 D stimulus, and 0.77+/-0.61 for the 4.00 D stimulus. Results were very similar at 45 and 60 min after drop instillation.
Combining 1% tropicamide and 1% cyclopentolate was very effective in providing both cycloplegia and mydriasis adequate for ocular biometry and cycloplegic refractions 30 min after drop instillation in African-American children.
睫状肌麻痹剂的选择取决于预期效果、用药患者的特征以及相关风险。奥林达近视纵向研究(OLSM)使用1%托吡卡胺评估了大量主要为白种儿童队列中的眼部成分和睫状肌麻痹验光结果。尽管托吡卡胺为OLSM队列提供了足够的睫状肌麻痹和散瞳效果,但传统临床经验和科学研究表明,托吡卡胺可能无法为虹膜色素沉着较深的受试者产生足够的睫状肌麻痹和散瞳效果。在本研究中,使用一滴1%托吡卡胺,随后再滴一滴1%环喷托酯,以确定它们在一组非裔美国儿童中进行睫状肌麻痹验光和眼部成分测量时产生足够睫状肌麻痹和散瞳效果的有效性。
19名儿童[年龄范围5.5至15.6岁,平均8.4岁±(标准差)2.5岁]在阿拉巴马州尤塔沃的阿拉巴马家庭医疗中心接受测试。在双眼滴入一滴0.5%丙美卡因、1%托吡卡胺(美多丽)和1%环喷托酯(赛飞杰)之前以及滴药后30、45和60分钟,使用佳能R-1自动验光仪测量他们的调节反应。位于+6.50屈光度(D)巴德尔透镜后面的4×4网格中的20/155字母目标提供了1.00D、2.00D和4.00D的调节刺激。
所有结果均以平均值±1标准差表示。从视频帧测量的瞳孔在滴入眼药水后30分钟迅速且最大程度地扩张(7.3±0.5毫米)。散瞳前,对于1.00D刺激,平均调节反应为0.17±0.29D;对于2.00D刺激,为1.01±0.40D;对于4.00D刺激,为2.77±0.74D。滴药后30分钟,对于1.00D刺激,反应为0.07±0.14D;对于2.00D刺激,为0.36±0.35D;对于4.00D刺激,为0.77±0.61D。滴药后45和60分钟的结果非常相似。
在非裔美国儿童中,将1%托吡卡胺和1%环喷托酯联合使用在滴药后30分钟为眼部生物测量和睫状肌麻痹验光提供足够的睫状肌麻痹和散瞳效果方面非常有效。